SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-18-001545
Filing Date
2018-08-13
Accepted
2018-08-13 17:11:01
Documents
38
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymx_6k.htm 6-K 8072
2 QUARTERLY REPORT FOR THE QUARTER ENDED nymx_ex991.htm EX-99.1 234375
3 CEO CERTIFICATION nymx_ex992.htm EX-99.2 10306
4 CFO CERTIFICATION nymx_ex993.htm EX-99.3 10430
11 nymx_ex991img2.jpg GRAPHIC 15687
  Complete submission text file 0001640334-18-001545.txt   1419340

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20180630.xml EX-101.INS 265537
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20180630.xsd EX-101.SCH 36884
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20180630_cal.xml EX-101.CAL 23463
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20180630_def.xml EX-101.DEF 38986
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20180630_lab.xml EX-101.LAB 112270
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20180630_pre.xml EX-101.PRE 85580
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 181013291
SIC: 2835 In Vitro & In Vivo Diagnostic Substances